Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | VCP | P55072 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HBB | P68871 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | HPRT1 | P00492 | 11/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | PNP | P00491 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valganciclovir SCHEMBL28996 | 1.00 | PDE3A (0.74) | PDE3AMEN1KMT2ABLMALDH1A1 | |
| Valganciclovir SCHEMBL23225 | 0.99 | PDE3A (0.73) | PDE3AMEN1KMT2ABLMALDH1A1 | |
| Valganciclovir SCHEMBL1652839 | 0.98 | PDE3A (0.71) | PDE3AMEN1KMT2ABLMALDH1A1 | |
| Valganciclovir SCHEMBL3237941 | 0.97 | PDE3A (0.70) | PDE3AMEN1KMT2ABLMALDH1A1 | |
| Valganciclovir SCHEMBL6479139 | 0.93 | PDE3A (0.68) | PDE3AMEN1KMT2ABLMALDH1A1 | |
| Valganciclovir SCHEMBL1120942 | 0.93 | PDE3A (0.85) | PDE3AMEN1KMT2ABLMALDH1A1 | |
| Valganciclovir SCHEMBL3134972 | 0.91 | PDE3A (0.62) | PDE3AMEN1KMT2ABLMALDH1A1 | |
| Valganciclovir SCHEMBL15251689 | 0.91 | PDE3A (0.83) | PDE3AMEN1KMT2ABLMALDH1A1 | |
| Valganciclovir SCHEMBL336814 | 0.88 | PDE3A (0.78) | PDE3AMEN1KMT2ABLMALDH1A1 | |
| Valganciclovir SCHEMBL18837501 | 0.88 | PDE3A (0.77) | PDE3AMEN1KMT2ABLMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13919 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144816-A1 | COMPOSITIONS AND METHODS FOR TREATING DEMENTIA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-28 | — | — | US | claimed |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4748448-A2 | USE OF MARIBAVIR FOR THE TREATMENT OF AND TREATMENT REGIMENS THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2026-05-27 | — | — | EP | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12611440-B2 | Fusion proteins and uses thereof | SYNKLINO A/S (DK) | 2026-04-28 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | claimed |
| US-20040022873-A1 | Systemic administration of NAC as an adjunct in the treatment of bioterror exposures such as anthrax, smallpox or radiation and for vaccination prophylaxis, and use in combination with DHEA for the treatment of smallpox and other viruses | Your Energy Systems, LLC | 2004-02-05 | — | — | US | claimed |
| US-20030207877-A1 | Pyridoquinoxaline antivirals | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | claimed |
| WO-2002064096-A9 | METHODS OF USING PYRIMIDINE-BASED ANTIVIRAL AGENTS | TULARIK INC (US) | 2003-10-16 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2003065988-A2 | A COMBINATION FOR TREATING COLD AND COUGH | PHARMACIA CORPORATION (US) | 2003-08-14 | — | — | WO | claimed |
| US-20030130264-A1 | Methods of using pyrimidine-based antiviral agents | TULARIK INC. (US) | 2003-07-10 | — | — | US | claimed |
| WO-2003053971-A1 | PYRIDOQUINOXALINE ANTIVIRALS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-03 | — | — | WO | claimed |
| WO-2002064096-A2 | METHODS OF USING PYRIMIDINE-BASED ANTIVIRAL AGENTS | TULARIK INC. (US) | 2002-08-22 | — | — | WO | claimed |
| US-6399622-B1 | EVALUATING PATIENT FOR EVIDENCE OF EPSTEIN-BARR VIRUS AND CYTOMEGALOVIRUS, ADMINISTERING ANTIVIRAL AGENTS | LERNER A MARTIN (US) | 2002-06-04 | — | — | US | claimed |
| US-20020037501-A1 | Evaluating patient for evidence of epstein-barr virus and cytomegalovirus, administering antiviral agents | LERNER A MARTIN (US) | 2002-03-28 | — | — | US | claimed |